Week in Review: BCVF Closes $188 Million China Life Sciences Fund

BVCF, a China private equity growth investor specializing in healthcare and life sciences, closed its third fund with capital of $188 million; Novartis and a unit of the World Bank were both investors in the fund; iKang Guobin Healthcare, which operates clinics in China, completed its $153 million IPO on the NASDAQ exchange, a transaction that valued the company at $903 million; Zhejiang Conba Pharma will pay $160.5 million to acquire a 51% stake in TCM-maker Guizhou Baite Pharma; Royal DSM, a Dutch science company, entered discussions to acquire Aland Nutraceutical of China, a vitamin C company; UCLA’s Department of Pathology will set up a clinical lab in Shanghai with Centre Testing International of China; WuXi PharmaTech received an innovation award for its recently completed cGMP biologics production facility; the US FDA still has only two drug inspectors in China, according to testimony last week; and TWi Pharma of Taiwan was granted approval to market a generic calcium-channel blocker in the US. More details…. Stock Symbols: (NYSE: NVS) (NSDQ: KANG) (SHA: 600572) (NYSE: WX) (TWO: 4180) Share this with colleagues: // //